Research Center for
Infectious Diseases and Substance Use
 |  |  |  |  |  |
|---|---|---|---|---|---|
 |  |  |  |  |  |
 |
With 27 years of experience in conducting HIV research including HIV vaccine, HIV biomedical prevention
and treatment in various populations to develop academic knowledge on HIV / AIDS,
we have worked in collaboration with leading international research networks and other domestic agencies.
Our diverse research programs are up-to-date with present situation and necessity of knowledge both nationally and globally
We are ready to expand our field of expertise to other challenging infectious diseases and substance use
News and Activities
To find more information, click on the image
RIHES Working Group for Buprenophine/naloxone Treatment Program attended the Conference on "Long Term Care for People with Opioid/Heroin Problems" at DONALD JEFFREY GIBSON Meeting Room, 2nd Floor, RIHES Building 1
Research Studies Currently Underway
To learn more, click Study title (to visit webpage) or Study snapshot (in Thai)
Contact Us
Research Institute for Health Sciences, Chiang Mai University
110 Intavaroros Road, Sriphum, Muang
Chiang Mai 50200 THAILAND
Tel. 66 5393 6148
A 5379
B-Enhancement of HBV Vaccination in Persons Living With HIV (BEe-HIVe): Evaluation of HEPLISAV-B
The purpose of this study is to evaluate response to and safety of the HBV vaccine HEPLISAV-B in two study populations living with HIV: prior HBV vaccine recipients who are deemed non-responders and individuals who are naïve to HBV vaccination.
Study vaccines: HEPLISAV-B vs. Engerix-B
What the body of children under 12 years of age living with HIV do to these drugs?
Are they safe for this population?
Abacavir/Dolutegravir/Lamivudine Dispersible and
Abacavir/Dolutegravir/Lamivudine Immediate Release Tablets
Respiratory syncytial virus (RSV) is a common and very contagious virus that infects the respiratory tract of most children before their second birthday. At present, there is no specific treatment
for RSV.
JNJ-53718678 is a novel drug and is under development for the treatment of RSV infection. This study purpose is to evaluate safety and antiviral activity of JNJ-53718678 in Children aged 28 days to 3 years with RSV infection